Cystic fibrosis beta

Goldman, M.J., et al., Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis, Cell. 88, 4, 553, 1997. 

A retrospective analysis of allergic reactions (drug-induced fever and rash) in 90 adults with cystic fibrosis, of whom 26 developed probable allergic reactions to parenteral beta-lactams. There was drug-induced fever in 54 and skin reactions in 28 of 897 treatment courses (6 and 3.1% respectively). There was one case of non-fatal anaphylaxis. The numbers of allergic reactions per number of patients receiving specific antibiotics were carbenicillin 4/56, mezlocillin 7/42, piperacillin 11/31, ticarcUlin 1/20, cefazolin 0/24, ceftazidime 1/35, imipenem + cilastatin 4/16, and nafcillin 3/36 (17). 

Koch C, Hjelt K, Pedersen SS, Jensen ET, Jensen T, Lanng S, Valerius NH, Pedersen M, Hoiby N. Retrospective clinical study of hypersensitivity reactions to aztreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses. Rev Infect Dis 1991 13(Suppl 7) S608-11. 

Pleasants RA, Walker TR, Samuelson WM. Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis. Chest 1994 106(4) 1124-8. 

Jensen T, Koch C, Pedersen SS, Hoiby N. Aztreonam for cystic fibrosis patients who are hypersensitive to other beta-lactams. Lancet 1987 l(8545) 1319-20. 

Rust P, Eichler I, Renner S, Elmadfa I. Effects of longterm oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. Int J Vitam Nutr Res 1998 68(2) 83-7. 

A number of antibiotics have been used as aerosol therapies. Examples include beta lactam agents, polymycin antimicrobials, neomycin, gentamicin, and tobramycin. Many of the early efforts were reported as case studies, and observations and data regarding safety and efficacy were lacking. Controlled clinical trials were not conducted until the middle of the 1980s. More recent evaluations have focused on the role of inhaled tobramycin used as suppressive therapy for cystic fibrosis patients colonized with Pseudomonas aeruginosa. 

WinkUiofer-Roob, B.M., Puhl, H., Khoschsorur, G., van t Hof, M.A., Esterbauer, H., and Shmerling, D.H., Enhanced resistance to oxidation of low density lipoproteins and decreased hpid peroxide formation during beta-carotene supplementation in cystic fibrosis. Free Radic. BiolMed., 18, 849,1995. 

Venkatakrishnan A, Stecenko AA, King G, Blackwell TR, Brigham KL, Christman JW, Blackwell TS. Exaggerated activation of nuclear factor-kappaB and altered DcappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2000 23 396. 

Arkwright PD, Laurie S, Super M, Pravica V, Schwarz MJ, Webb AK, Hutchinson IV. TGF-beta(l) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 2000 55 459. 

---